Continuous Administration of Dexmedetomidine in Neurosurgical Patients

Agustina Br Haloho[1], Ferdy Rahadiyan[2]
[1]Lecturer, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Sriwijaya
[2]Resident, Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Sriwijaya
Email:ferdyrahadiyan@gmail.com

Abstract

Neurosurgical procedures, including craniectomy for tumor resection, epilepsy surgery, aneurysm clipping, and neuroradiological interventions, often present significant challenges in postoperative pain management. Traditional opioid-based analgesia is associated with risks such as respiratory depression, increased intracranial pressure, and interference with neurological assessments. As a result, opioid-free anesthesia strategies have gained attention, with dexmedetomidine (DEX) playing a crucial role. DEX, a highly selective α2-adrenergic agonist, provides sedative, analgesic, and anesthetic effects without causing significant respiratory depression. This review explores the continuous administration of dexmedetomidine in neurosurgical patients, evaluating its impact on hemodynamic stability and its potential to reduce perioperative opioid use while maintaining intraoperative hemodynamic control. The findings suggest that dexmedetomidine offers advantages in postoperative pain management, reduces sympathetic responses, and minimizes opioid-related side effects, ultimately improving patient outcomes. However, further studies are necessary to establish standardized dosing protocols and assess long-term efficacy and safety in neurosurgical populations.

Keywords: Dexmedetomidine, neurosurgical anesthesia, opioid-free anesthesia, perioperative pain management, hemodynamic stability, neuroprotection.

Introduction

Neurosurgical procedures, such as craniectomy for tumor resection, epilepsy surgery, aneurysm clipping, and neuroradiological interventions, are associated with significant postoperative pain and potential complications, making perioperative management a critical concern.[1] Postoperative complications, including hematoma formation, increased intracranial pressure, cerebral infarction, seizures, hypertension, cranial nerve injuries, and cerebral edema, can exacerbate pain and negatively impact patient prognosis.[1,2]

Studies indicate that 40% to 84% of neurosurgical patients experience moderate to severe postoperative pain. Inadequate pain management following craniectomy can lead to secondary complications such as anxiety, hypertension, increased intracranial pressure, and even postoperative intracerebral hemorrhage. Despite the high prevalence of pain, its management in neurosurgical patients remains suboptimal due to concerns about opioid administration. Opioids, while effective for moderate to severe pain, may obscure neurological assessments, induce respiratory depression, and contribute to increased intracranial pressure, further complicating postoperative recovery.[1,3,4]

Given these concerns, the concept of opioid-free anesthesia has been explored as an alternative in neurosurgical settings. Dexmedetomidine (DEX), a highly selective α2-adrenergic agonist, has emerged as a promising adjunct for perioperative pain control. DEX offers sedative, analgesic, and anesthetic effects while minimizing respiratory depression and preserving hemodynamic stability. Additionally, it demonstrates potential neuroprotective properties, making it an attractive option for neurosurgical anesthesia.[5,6]

This study aims to evaluate the continuous administration of dexmedetomidine in neurosurgical patients, focusing on its effects on hemodynamics, perioperative pain control, and potential as an anesthetic adjuvant. A better understanding of DEX's role in neurosurgical anesthesia may contribute to optimizing pain management strategies, improving surgical outcomes, and enhancing overall patient care in neurosurgery.

Anesthesia in Neurosurgery

Neuroanesthesia in Neurosurgery

Advancements in neuroanesthesia since the mid-20th century have focused on understanding brain injury mechanisms, neuroprotection, and the effects of anesthetic agents on relevant

neuroanatomy, along with clinical practices in induction, maintenance, and limiting neuroanesthesia.[7] Maintaining stable hemodynamics and ensuring brain tissue perfusion are crucial, while monitoring intracranial pressure changes. Most anesthetics reduce brain oxygen demand, but volatile agents, nitrous oxide, and ketamine increase cerebral blood flow, while intravenous agents may reduce it. These changes affect cerebral autoregulation, vasomotor reactivity, and neurovascular connections.[8] Volatile anesthetics and propofol reduce cerebral autoregulation at high doses, while synthetic opioids increase cerebral blood flow through vasodilation. Elevated PaCO2 induces vasodilation, improving blood flow, but some volatile agents and propofol decrease vasomotor reactivity. Neurovascular connections are influenced by anesthetics affecting nerve activity and signal transmission.[8]

Pain Management in Neurosurgery

Mordhorst et al. (2010) found that 55% of patients experience moderate to severe pain in the first 24 hours after craniectomy.[9] This is consistent with a study by De Benedittis et al., which reported 60% of patients experiencing postoperative pain.[10] The highest incidence of postoperative pain occurs after subtemporal and suboccipital craniectomy, while frontal craniectomy causes less pain. The pain is often described as pulsatile or continuous. Women, younger patients, and those using preoperative opioids are more likely to experience pain.[1] The pain is usually somatic, originating from soft tissues and pericranial muscles, not the brain itself, and is typically nociceptive, triggered by surgical incisions and muscle stress.[1]

Table 1. Commonly Used Sedation Doses[11]

Drug	Intermittent Dose	Continuous Dose
Fentanyl	0.35–0.5 mcg/kg every 0.5–1 hour	0.7–10 mcg/kg/hour
Hydromorphone	10–30 mcg/kg every 1–2 hours	7–15 mcg/kg/hour
Morphine	0.01–0.15 mg/kg every 1–2 hours	0.07–0.05 mg/kg/hour
Methadone	10–40 mg orally every 6–12 hours	Not recommended
Diazepam	0.03–0.1 mg/kg every 0.5–6 hours	-
Lorazepam	0.02–0.06 mg/kg every 2–6 hours	0.01–0.1 mg/kg/hour
Midazolam	0.02–0.08 mg/kg every 0.5–2 hours	0.04–0.2 mg/kg/hour

Propofol	Induction dose: 1–2.5 mg/kg	5–80 mcg/kg/min
Ketamine	Induction dose: 1–4.5 mg/kg IV	0.12–0.4 mg/kg/hour
	Intramuscular dose: 6–13 mg/kg × 1	
	Acute pain: 0.5–1 mg/kg every 15 minutes	
	Procedural sedation: 1–2 mg/kg every 5–15 minutes	
Dexmedetomidine	-	Loading dose of 0.5–1 mcg/kg over 10 minutes before the infusion:
		ICU sedation: 0.2–0.7 mcg/kg/hour
		Intubation: 0.6–0.7 mcg/kg/hour

Postoperative pain is often managed with opioids after major surgeries, but their use in neurosurgery is limited due to concerns about their effects on neurological assessments, such as obscuring intracranial events, sedation, miosis, respiratory depression, and increased intracranial pressure.[1,4] Remifentanil-induced hyperalgesia may worsen postoperative pain and increase analgesic needs.[1,2,5]

Dexmedetomidine

Definition

Dexmedetomidine is a potent α2-adrenergic agonist that provides sedation and analgesia without respiratory depression. It is widely used clinically for sedation and anesthesia. α2-adrenergic agonists are cerebral vasoconstrictors that reduce cerebral blood flow (CBF) with little impact on cerebral metabolic oxygen demand (CMRO2). Dexmedetomidine has shown to improve post-operative recovery, reduce opioid prescriptions, lower sympathetic tone, inhibit inflammatory reactions, and protect organs. Animal studies also suggest that it enhances neurological outcomes in brain and spinal cord injuries. Additionally, clinical trials report its effectiveness in reducing post-operative neurological dysfunction like delirium and stroke.[3,12,13]

Dexmedetomidine administration before major inpatient surgeries has significantly reduced opioid requirements. However, it is not yet used as a sole therapy during general anesthesia, though it can be beneficial as part of multimodal anesthesia strategies.[12]

Mechanism of Action

Dexmedetomidine inhibits norepinephrine release at the locus coeruleus, leading to sedation and reduced alertness. This sedation differs from other sedatives and is often described as "cooperative sedation." It does not consistently produce amnesia, so it should not be used as the sole anesthetic agent when amnesia is the primary goal. Dexmedetomidine also affects presynaptic C fibers and postsynaptic spinal neurons, making it useful for patients receiving intrathecal analgesia, extending the duration of local anesthetic motor and sensory blockade.[11]

Pharmacokinetics

Dexmedetomidine, though approved for intravenous (IV) use, can be administered extravascularly to avoid high peak plasma levels. Oral administration shows 16% bioavailability. It is highly protein-bound in plasma (94%) and has a volume of distribution of 1.31-2.46 L/kg in healthy volunteers. The drug is primarily metabolized by the liver, with less than 1% excreted unchanged. Its elimination half-life ranges from 2.1-3.1 hours in healthy subjects.[15]

Pharmacodynamics

Dexmedetomidine, used alone or with remifentanil, provides a safe and acceptable condition for awake neurosurgical procedures. It allows neurological assessments without causing tachycardia or hypertension. Additionally, it has neuroprotective effects, including reduced intracranial pressure and cerebral blood flow.[16]

Sedative Effects

The sedation produced by dexmedetomidine resembles natural sleep and is mediated by α2-receptor activation. At plasma concentrations between 0.2 and 0.3 ng/mL, significant sedation occurs, with unarousable sedation at concentrations above 1.9 ng/mL. Dexmedetomidine is approved for procedural sedation in the U.S., with significant findings showing fewer patients requiring midazolam rescue during procedures.[15]

Analgesic Effects

Dexmedetomidine’s analgesic effects are mediated by α2-receptor binding in the central nervous system and spinal cord. However, it does not provide adequate analgesia alone at concentrations up to 1.23 ng/mL. The analgesic effect might be partly due to reduced anxiety and altered perception, especially when used in combination with local anesthetic techniques.[15]

Cardiovascular Effects

Dexmedetomidine induces a biphasic hemodynamic response, leading to hypotension at low concentrations and hypertension at higher concentrations. The initial phase involves increased blood pressure and decreased heart rate, followed by vasodilation and hypotension as the drug concentration decreases.[15]

Respiratory Effects

Dexmedetomidine can reduce the ventilatory response to hypercapnia, especially in older patients. Its use with other sedatives or analgesics increases the risk of respiratory depression or apnea, requiring careful monitoring in intensive care settings.[15]

Dosing and Administration

Dexmedetomidine is approved for IV sedation in the ICU and procedural sedation, with typical loading doses ranging from 0.5–1.0 μg/kg over 10 minutes, followed by a maintenance infusion of 0.3–1.0 μg/kg/h. Lower doses are recommended for elderly patients or those with hypertension. It can also be used intranasally for pediatric or geriatric patients, with a dose of 0.5–2 μg/kg.[15]

Table 2. Dexmedetomidine Dosing and Administration Rates[12]

Administration Type	Loading Dose (μg/kg)	Continuous Dose (μg/kg/hr)	
Procedural Sedation	0.5–1.0 (in 10 min)	0.3–1.0	
Anesthesia Adjunct	0.5–1.0 (in 10 min)	0.3–0.5	
Intranasal	0.5–2 μg/kg	-	

The recommended dosing for dexmedetomidine includes an initial loading dose of 1 μg/kg over 10 minutes, followed by a continuous infusion of 0.2-0.7 μg/kg/hr. It is also noted for its dose-dependent effects on heart rate, cardiac output, and catecholamine circulation. Studies suggest reducing the loading dose in cases where other sedative agents have been used.[18,19]

Application in Neuroanesthesia

A study by Batra et al. (2017) found that continuous infusion of dexmedetomidine before surgery maintained hemodynamic stability and effectively reduced cardiovascular responses to intubation, skull pin placement, and extubation, while lowering the need for other anesthetics.[6]

Cerebrovascular Disease

Carotid Endarterectomy (CEA) is often required for significant carotid artery disease. Patients

undergoing CEA may experience hemodynamic fluctuations and reduced cerebral blood flow due to dexmedetomidine use, which could increase the risk of inadequate oxygen delivery, potentially requiring an intracarotid shunt. Although dexmedetomidine doesn't increase the incidence of shunt use compared to controls, postoperative hypotension and the need for additional hemodynamic interventions are more common. Some patients may also experience cerebral hyperperfusion post-CEA, potentially causing neurological deficits. Further research is needed to understand its effects on cerebral autoregulation in CEA patients.[17]

Intracranial Tumor Surgery

Dexmedetomidine has been shown to help maintain stable hemodynamics during intracranial tumor resections, preventing sudden increases in intracranial pressure. A study found that using dexmedetomidine as an anesthetic adjunct resulted in fewer cardiovascular fluctuations and faster recovery compared to other agents, and was associated with fewer neurological deficits post-surgery.[17]

Surgical Procedures Requiring Intraoperative Mapping

Dexmedetomidine is increasingly used in awake craniotomies, where the patient remains conscious for brain mapping. It helps maintain stable hemodynamics and minimizes cardiovascular variations during the procedure. Studies show that dexmedetomidine results in fewer neurological deficits post-surgery compared to other anesthetics.[17]

Stereotactic Neurosurgery

For deep brain stimulator (DBS) implantation, dexmedetomidine is preferred over propofol and benzodiazepines. DBS, used for treating movement disorders, requires the patient to remain alert. While other sedatives can interfere with clinical presentations, dexmedetomidine provides effective sedation without disrupting neuronal recordings. It also reduces intraoperative hypertension and tachycardia, lowering the risk of complications like intracranial hemorrhage.[12]

Conclusion

Neurosurgical procedures, such as craniectomy, aneurysm clipping, and brain tumor surgery, often result in severe postoperative pain and complications like hematoma, increased intracranial pressure, and seizures. Opioids, commonly used for pain management, can cause respiratory depression and worsen intracranial pressure.

The "opioid-free anesthesia" approach, using agents like dexmedetomidine, offers a safer alternative. Dexmedetomidine provides sedation, analgesia, and anesthesia without significantly affecting respiration, making it ideal for neurosurgery patients. It maintains hemodynamic stability, reduces cardiovascular responses, and aids in intraoperative mapping.

Further research on dexmedetomidine in neurosurgery could enhance patient care by better understanding its benefits and risk.

REFERENCES

1. Vadivelu N, Kai AM, Tran D, Kodumudi G, Legler A, Ayrian E. Options for perioperative pain management in neurosurgery. J Pain Res. 2016 Feb;9:37–47.
2. Sriganesh K, Syeda S, Shanthanna H, Venkataramaiah S, Palaniswamy SR. Effect of Opioid Versus Non-Opioid Analgesia on Surgical Pleth Index and Biomarkers of Surgical Stress During Neurosurgery for Brain Tumors: Preliminary Findings. Neurol India. 2020 Sep;68(5):1101.
3. Liu Y, Liang F, Liu X, Shao X, Jiang N, Gan X. Dexmedetomidine Reduces Perioperative Opioid Consumption and Postoperative Pain Intensity in Neurosurgery: A Meta-analysis. J Neurosurg Anesthesiol. 2018;30(2):146–55.
4. Bab BJ, Anestesiologi BP, Lingkungan B, Operasi R, Pernapasan BS, Stasiun B, et al. Morgan & Mikhail ' s Clinical Anesthesiology 6 th ed.
5. Sethuraman M, Bidkar PU, Mariappan R, Deopujari RC, Vanamoorthy P, Massand M. Recent advancements in the practice of neuroanaesthesia and neurocritical care: An update. Indian J Anaesth. 2023 Jan;67(1):85.
6. Batra A, Verma R, Bhatia VK, Chandra G, Bhushan S. Dexmedetomidine as an Anesthetic Adjuvant in Intracranial Surgery. Anesth Essays Res. 2017;11(2):309.
7. Nguyen LP, Gerstein NS. Cardiovascular pharmacology in noncardiac surgery. In: Essentials of Cardiac Anesthesia for Noncardiac Surgery: A Companion to Kaplan's Cardiac Anesthesia. Elsevier; 2018. p. 247–88.
8. Nguyen A, Mandavalli A, Diaz MJ, Root KT, Patel A, Casauay J, et al. Neurosurgical Anesthesia: Optimizing Outcomes with Agent Selection. Biomed 2023, Vol 11, Page 372. 2023 Jan;11(2):372.
9. Mordhorst C, Latz B, Kerz T, Wisser G, Schmidt A, Schneider A, et al. Prospective assessment of postoperative pain after craniotomy. J Neurosurg Anesthesiol. 2010 Jul;22(3):202–6.
10. De Benedittis G, Lorenzetti A, Migliore M, Spagnoli D, Tiberio F, Villani RM. Postoperative pain in neurosurgery: a pilot study in brain surgery. Neurosurgery. 1996 Mar;38(3):466–70.
11. Prabhakar H, Ali Z. Textbook of Neuroanesthesia and Critical Care Volume II - Neurocritical Care. Vol. 13, Springer Nature Singapore. Singapore: Springer Singapore;

2019.

12. Tasbihgou SR, Barends CRM, Absalom AR. The role of dexmedetomidine in neurosurgery. Best Pract Res Clin Anaesthesiol. 2021 Jul;35(2):221–9.
13. Liaquat Z, Xu X, Zilundu PLM, Fu R, Zhou L. The Current Role of Dexmedetomidine as Neuroprotective Agent: An Updated Review. Brain Sci 2021, Vol 11, Page 846. 2021 Jun;11(7):846.
14. Cai Q, Liu G, Huang L, Guan Y, Wei H, Dou Z, et al. The Role of Dexmedetomidine in Tumor-Progressive Factors in the Perioperative Period and Cancer Recurrence: A Narrative Review. Drug Des Devel Ther. 2022;16:2161–75.
15. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet. 2017 Aug;56(8):893.
16. Lee S. Dexmedetomidine: present and future directions. Korean J Anesthesiol. 2019 Aug;72(4):323.
17. Lin N, Vutskits L, Bebawy JF, Gelb AW. Perspectives on Dexmedetomidine Use for Neurosurgical Patients. J Neurosurg Anesthesiol. 2019 Oct;31(4):366–77.
18. Kung HC, Cheng CC, Kang DH, Jeong HJ, Shin YS, Kim DS, et al. The effects of loading dose administration rate of dexmedetomidine on sedation and dexmedetomidine requirement in elderly patients undergoing spinal anesthesia. Anesth Pain Med. 2018 Jul;13(3):264–70.
19. Ickeringill M, Shehabi Y, Adamson H, Ruettimann U. Original Papers Dexmedetomidine Infusion Without Loading Dose in Surgical Patients Requiring Mechanical Ventilation: Haemodynamic Effects and Efficacy. Vol. 32, Anaesthesia and Intensive Care. 2004.